Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Hepatic Encephalopathy Market Size And Revenue Outlook Through 2030
The hepatic encephalopathy market has exhibited strong growth in recent years. It is projected to increase from $1.8 billion in 2025 to $1.89 billion in 2026, at a compound annual growth rate (CAGR) of 5.0%. This historical growth can be attributed to factors like the rising prevalence of chronic liver diseases, increased alcohol consumption rates, a higher incidence of cirrhosis, enhanced diagnostic awareness, and the expansion of specialty liver care centers.
The market for hepatic encephalopathy is projected to experience substantial expansion in the coming years, set to reach $2.38 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 6.0%. Factors driving this growth during the forecast period include a rising demand for cutting-edge therapeutics, an increase in liver transplant operations, a heightened emphasis on lowering hospitalization rates, the broadening of digital monitoring solutions, and increased funding for hepatology research. Key trends anticipated during this period encompass the growing acceptance of targeted drug therapies, an increase in the application of combination treatment plans, a greater emphasis on prompt diagnosis and consistent monitoring, the widening of hospital-based treatment guidelines, and improved patient-focused care strategies.
Get A Free Sample Report With In-Depth Market Insights:
Hepatic Encephalopathy Market Growth Factors: What’s Supporting Expansion?
The escalating incidence of liver diseases is projected to fuel the expansion of the hepatic encephalopathy market. Liver disease is defined as a medical condition impacting the liver and impairing its functional capacity. Treatments for liver disease, such as those for hepatic encephalopathy, have the potential to ease symptoms, decelerate disease progression, enhance liver function, and diminish the occurrence of hepatic encephalopathy by improving the management of underlying health conditions. This can potentially reduce the frequency and severity of episodes and elevate patients’ overall quality of life. For instance, in April 2024, data from the Office for Health Improvement and Disparities, a UK government department, revealed that hospital admission rates for liver disease continued their upward trend, reaching 155.2 per 100,000 population (with a range of 152.9 to 157.5) in the financial year concluding 2023, an increase from 150.6 (148.2 to 152.9) reported in the prior year. Consequently, the rising prevalence of liver diseases is a key driver for the hepatic encephalopathy market.
Hepatic Encephalopathy Market Segment Analysis: What Are The Core Market Categories?
The hepatic encephalopathy market covered in this report is segmented –
1) By Drug Class: Antibiotics, Laxatives
2) By Route Of Administration: Oral, Intravenous, Rectal
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies
Subsegments:
1) By Antibiotics: Rifaximin, Neomycin
2) By Laxatives: Lactulose, Polyethylene Glycol
Hepatic Encephalopathy Market Trends Shaping Long-Term Demand
Major companies operating in the hepatic encephalopathy market are developing innovative drugs to treat the condition, aiming to gain competitive advantages and strengthen their position. For instance, in June 2023, Karolinska Development AB, a Sweden-based pharmaceutical company, developed the novel GR3027 (golexanolone) specifically for treating hepatic encephalopathy. This orally administered small molecule acts as a GABAA-receptor-modulating steroid antagonist (GAMSA), designed to antagonize the positive GABAA-receptor modulation by endogenous neuroactive steroids. Additionally, the drug is being investigated for HE, with its trial currently being conducted for CHE in Phases I/IIa.
Hepatic Encephalopathy Market Top Companies Driving Competitive Growth
Major companies operating in the hepatic encephalopathy market are Salix Pharmaceuticals, Bausch Health Companies, Norgine, Lupin, Sun Pharmaceutical Industries, Dr Reddys Laboratories, Cipla, Teva Pharmaceutical Industries, Mylan, Torrent Pharmaceuticals, Amneal Pharmaceuticals, Zydus Lifesciences, Aurobindo Pharma, Intas Pharmaceuticals, Alkem Laboratories, Alembic Pharmaceuticals, Wockhardt, Hetero Drugs, Cadila Pharmaceuticals, Abbott India
View The Full Hepatic Encephalopathy Market Report:
Hepatic Encephalopathy Market Geographic Analysis: Where Is Demand Rising Fastest?
North America was the largest region in the hepatic encephalopathy market in 2025. The regions covered in the hepatic encephalopathy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model









